Topotarget Overview

  • Founded
  • 2000
  • Status
  • Acquired/​Merged
  • Employees
  • 13
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $108M
Latest Deal Amount

Topotarget General Information


Producer of biopharmaceutical products. The company engages in clinical development and registration of oncology products. It primarily develops drugs for the treatment of hematological malignancies, solid tumors and cancer therapies.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Fruebjergvej 3
  • 2100 Copenhagen
  • Denmark
+45 39 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Topotarget Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 05-Aug-2014 $108M 00000 Completed Profitable
1. Early Stage VC Completed Startup
To view Topotarget’s complete valuation and funding history, request access »

Topotarget Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Topotarget Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Banexi Ventures Partners Venture Capital Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0
To view Topotarget’s complete investors history, request access »

Topotarget Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 27-Jun-2007 0000000000 000.00 Therapeutic Devices 000000 00
Prolifix 04-Jun-2002 Merger/Acquisition Biotechnology 000000 00
To view Topotarget’s complete acquisitions history, request access »